iSTAR MIGS Procedure Effective at 18 Months

■ iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, has announced consistent 18-month results of the first-in-human MIGS STAR-I trial for the MINIject device in a standalone setting. The company says these results confirm the stability and sustained performance of MINIject beyond the first year.

The STAR-I trial demonstrated that the implantation of MINIject resulted in a mean pressure of 15.0 mmHg at 18 months, consistent with results reported at 1 year and at a level expected to reduce the progression of glaucoma. In addition, almost two-thirds of the patients were able to stop taking their eye drops. These results confirm that the safety and effectiveness of MINIject is sustained over time, with minimal patient management required.